From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Podcasts|August 5, 2022
Pharmacy Focus Episode 52: A Thank You to Our Listeners!
We couldn't get to where we are at today without your amazing support!
Advertisement
In this week's episode, host Jill Murphy shares a special message for her growing listeners of Pharmacy Focus. Additionally, she talks about all of the new series that have been created since the birth of the podcast.
To be a guest on any of our shows or episode suggestions: JMurphy@pharmacytimes.com
For Pharmacy Heroes: AAntrim@pharmacytimes.com
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5